There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clover Health Investments (CLOV – Research Report), ClearPoint Neuro (CLPT – Research Report) and Xtant Medical Holdings (XTNT – Research Report) with bullish sentiments.
Stay Ahead of the Market:
Clover Health Investments (CLOV)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Clover Health Investments today. The company’s shares closed last Wednesday at $3.69.
According to TipRanks.com, Hewitt is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.2% and a 38.4% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, InfuSystem Holdings, Inc., and Lifecore Biomedical.
Currently, the analyst consensus on Clover Health Investments is a Moderate Buy with an average price target of $4.33, which is a 16.7% upside from current levels. In a report issued on April 7, Canaccord Genuity also maintained a Buy rating on the stock with a $4.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
ClearPoint Neuro (CLPT)
Lake Street analyst Frank Takkinen maintained a Buy rating on ClearPoint Neuro today. The company’s shares closed last Wednesday at $11.52.
According to TipRanks.com, Takkinen is ranked 0 out of 5 stars with an average return of -3.9% and a 30.0% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Inspire Medical Systems, and TriSalus Life Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ClearPoint Neuro with a $25.00 average price target.
Xtant Medical Holdings (XTNT)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Xtant Medical Holdings today. The company’s shares closed last Wednesday at $0.40, close to its 52-week low of $0.33.
According to TipRanks.com, Knickerbocker is ranked 0 out of 5 stars with an average return of -5.9% and a 31.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Fennec Pharmaceuticals, and Diamedica Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xtant Medical Holdings with a $2.00 average price target.
Read More on CLOV: